Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study (supplemental materials)

Supplemental materials for the manuscript: 'Bimekizumab for patients with moderate- to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.' Includes supplemental methods for the BE ABLE 2 phase 2b trial, patient demographics and baseline characteristics, incidence of serious treatment-emergent adverse events in the trail, patient disposition flowchart, PASI90 reponse rates over time in Week 12 PASI90 responder and non-responder subgroups, and PASI100 response rates over time in Week 12 PASI90 responders.

本补充材料对应学术论文《比美珠单抗用于中重度斑块状银屑病患者：来自BE ABLE 2 2b期随机双盲安慰剂对照延伸试验的60周结果》。本材料包含BE ABLE 2 2b期试验的补充方法学内容、受试者人口统计学特征与基线特征、试验中严重治疗突发不良事件的发生率、受试者处置流程图、第12周银屑病面积和严重程度指数（Psoriasis Area and Severity Index，PASI）90应答亚组与非应答亚组的PASI90应答率随时间变化情况，以及第12周PASI90应答者的PASI100应答率随时间变化情况。